{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:32:08Z","timestamp":1770262328219,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10096-025-05302-6","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:11:11Z","timestamp":1760447471000},"page":"217-225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Isolation and characterization of a lytic phage and its efficacy against multi-drug resistant strains of pseudomonas aeruginosa"],"prefix":"10.1007","volume":"45","author":[{"given":"Mohammad","family":"Sarmast","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Peeri-Dogaheh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiman","family":"Karami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzad","family":"Khademi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"5302_CR1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212527","volume":"7","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, Vena A, Croxatto A (2018) How to manage Pseudomonas aeruginosa infections. Drugs Context 7:212527. https:\/\/doi.org\/10.7573\/dic.212527","journal-title":"Drugs Context"},{"issue":"10","key":"5302_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s10096-013-1876-y","volume":"32","author":"MC Gaspar","year":"2013","unstructured":"Gaspar MC, Couet W, Olivier JC et al (2013) Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur J Clin Microbiol Infect Dis 32(10):1231\u20131252. https:\/\/doi.org\/10.1007\/s10096-013-1876-y","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"5302_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40121-022-00591-2","volume":"11","author":"AJ Kunz Coyne","year":"2022","unstructured":"Kunz Coyne AJ, El Ghali A, Holger D et al (2022) Therapeutic strategies for emerging Multidrug-Resistant Pseudomonas aeruginosa. Infect Dis Ther 11(2):661\u2013682. https:\/\/doi.org\/10.1007\/s40121-022-00591-2","journal-title":"Infect Dis Ther"},{"issue":"1","key":"5302_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01056-1","volume":"7","author":"S Qin","year":"2022","unstructured":"Qin S, Xiao W, Zhou C et al (2022) Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther 7(1):199. https:\/\/doi.org\/10.1038\/s41392-022-01056-1","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"5302_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","volume":"37","author":"Z Pang","year":"2019","unstructured":"Pang Z, Raudonis R, Glick BR (2019) Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv 37(1):177\u2013192. https:\/\/doi.org\/10.1016\/j.biotechadv.2018.11.013","journal-title":"Biotechnol Adv"},{"key":"5302_CR6","doi-asserted-by":"publisher","unstructured":"Sommer LM, Johansen HK, Molin S (2020) Antibiotic resistance in Pseudomonas aeruginosa and adaptation to complex dynamic environments. Microb Genom 6(5). https:\/\/doi.org\/10.1099\/mgen.0.000370","DOI":"10.1099\/mgen.0.000370"},{"key":"5302_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10020145","author":"A Vaitekenas","year":"2021","unstructured":"Vaitekenas A, Tai AS, Ramsay JP et al (2021) Pseudomonas aeruginosa resistance to bacteriophages and its prevention by strategic therapeutic cocktail formulation. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics10020145","journal-title":"Antibiotics"},{"issue":"18","key":"5302_CR8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","volume":"81","author":"D Reynolds","year":"2021","unstructured":"Reynolds D, Kollef M (2021) The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update. Drugs 81(18):2117\u20132131. https:\/\/doi.org\/10.1007\/s40265-021-01635-6","journal-title":"Drugs"},{"issue":"2","key":"5302_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/phage.2020.29004.has","volume":"1","author":"HA Sohail","year":"2020","unstructured":"Sohail HA, Coffey A, Debrowska K et al (2020) Bacteriophages: emerging applications in Medicine, Food, and biotechnology. Phage (New Rochelle) 1(2):75\u201382. https:\/\/doi.org\/10.1089\/phage.2020.29004.has","journal-title":"Phage (New Rochelle)"},{"issue":"5","key":"5302_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21315\/mjms2023.30.5.2","volume":"30","author":"F Raees","year":"2023","unstructured":"Raees F, Harun A, Ahmed A (2023) Potential usefulness of bacteriophages for the treatment of multidrug-resistant acinetobacter infection. Malays J Med Sci 30(5):7\u201322. https:\/\/doi.org\/10.21315\/mjms2023.30.5.2","journal-title":"Malays J Med Sci"},{"issue":"9","key":"5302_CR11","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1111\/ajt.15503","volume":"19","author":"S Aslam","year":"2019","unstructured":"Aslam S, Courtwright AM, Koval C et al (2019) Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant 19(9):2631\u20132639. https:\/\/doi.org\/10.1111\/ajt.15503","journal-title":"Am J Transplant"},{"issue":"2","key":"5302_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","volume":"25","author":"KE Kortright","year":"2019","unstructured":"Kortright KE, Chan BK, Koff JL et al (2019) Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe 25(2):219\u2013232. https:\/\/doi.org\/10.1016\/j.chom.2019.01.014","journal-title":"Cell Host Microbe"},{"issue":"2","key":"5302_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4161\/bact.1.2.14590","volume":"1","author":"C Loc-Carrillo","year":"2011","unstructured":"Loc-Carrillo C, Abedon ST (2011) Pros and cons of phage therapy. Bacteriophage 1(2):111\u2013114. https:\/\/doi.org\/10.4161\/bact.1.2.14590","journal-title":"Bacteriophage"},{"issue":"1","key":"5302_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-020-00389-5","volume":"19","author":"Z Chegini","year":"2020","unstructured":"Chegini Z, Khoshbayan A, Taati Moghadam M et al (2020) Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review. Ann Clin Microbiol Antimicrob 19(1):45. https:\/\/doi.org\/10.1186\/s12941-020-00389-5","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"11","key":"5302_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ph14111157","volume":"14","author":"ST Abedon","year":"2021","unstructured":"Abedon ST, Danis-Wlodarczyk KM, Alves DR (2021) Phage therapy in the 21st century: is there modern, clinical evidence of phage-mediated efficacy? Pharmaceuticals (Basel) 14(11):1157. https:\/\/doi.org\/10.3390\/ph14111157","journal-title":"Pharmaceuticals (Basel)"},{"key":"5302_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12040751","author":"K Diallo","year":"2023","unstructured":"Diallo K, Dublanchet A (2023) A century of clinical use of phages: a literature review. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics12040751","journal-title":"Antibiotics"},{"key":"5302_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.mib.2019.03.005","volume":"51","author":"AM Segall","year":"2019","unstructured":"Segall AM, Roach DR, Strathdee SA (2019) Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy. Curr Opin Microbiol 51:46\u201350. https:\/\/doi.org\/10.1016\/j.mib.2019.03.005","journal-title":"Curr Opin Microbiol"},{"issue":"1","key":"5302_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-024-03309-1","volume":"24","author":"S Jafari-Ramedani","year":"2024","unstructured":"Jafari-Ramedani S, Nazari M, Arzanlou M (2024) Prevalence and molecular characterization of colistin resistance in Pseudomonas aeruginosa isolates: insights from a study in Ardabil hospitals. BMC Microbiol 24(1):152. https:\/\/doi.org\/10.1186\/s12866-024-03309-1","journal-title":"BMC Microbiol"},{"issue":"1","key":"5302_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09585-6","volume":"24","author":"N Saeli","year":"2024","unstructured":"Saeli N, Jafari-Ramedani S, Ramazanzadeh R et al (2024) Prevalence and mechanisms of aminoglycoside resistance among drug-resistant Pseudomonas aeruginosa clinical isolates in Iran. BMC Infect Dis 24(1):680. https:\/\/doi.org\/10.1186\/s12879-024-09585-6","journal-title":"BMC Infect Dis"},{"issue":"1","key":"5302_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00284-019-01792-8","volume":"77","author":"Y-H Jiang","year":"2019","unstructured":"Jiang Y-H, Liu J-Q, Zhao C-Y et al (2019) Isolation and genome sequencing of a novel Pseudomonas aeruginosa phage PA-YS35. Curr Microbiol 77(1):123\u2013128. https:\/\/doi.org\/10.1007\/s00284-019-01792-8","journal-title":"Curr Microbiol"},{"key":"5302_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.biologicals.2019.10.003","volume":"63","author":"M Adnan","year":"2020","unstructured":"Adnan M, Ali Shah MR, Jamal M (2020) Isolation and characterization of bacteriophage to control multidrug-resistant Pseudomonas aeruginosa planktonic cells and biofilm. Biologicals 63:89\u201396. https:\/\/doi.org\/10.1016\/j.biologicals.2019.10.003","journal-title":"Biologicals"},{"key":"5302_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/7077344","volume":"2021","author":"L Ahmadian","year":"2021","unstructured":"Ahmadian L, Norouzi Bazgir Z, Ahanjan M et al (2021) Role of aminoglycoside-modifying enzymes (AMEs) in resistance to aminoglycosides among clinical isolates of Pseudomonas aeruginosa in the north of Iran. BioMed Res Int 2021:7077344. https:\/\/doi.org\/10.1155\/2021\/7077344","journal-title":"BioMed Res Int"},{"issue":"1","key":"5302_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-021-02197-z","volume":"21","author":"BL Aghaee","year":"2021","unstructured":"Aghaee BL, Mirzaei MK, Alikhani MY et al (2021) Sewage and sewage-contaminated environments are the most prominent sources to isolate phages against Pseudomonas aeruginosa. BMC Microbiol 21(1):132. https:\/\/doi.org\/10.1186\/s12866-021-02197-z","journal-title":"BMC Microbiol"},{"key":"5302_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9030478","author":"EV Fiscarelli","year":"2021","unstructured":"Fiscarelli EV, Rossitto M, Rosati P (2021) In vitro newly isolated environmental phage activity against biofilms preformed by Pseudomonas aeruginosa from patients with cystic fibrosis. Microorganisms. https:\/\/doi.org\/10.3390\/microorganisms9030478","journal-title":"Microorganisms"},{"issue":"1","key":"5302_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-022-00492-9","volume":"21","author":"B Sisakhtpour","year":"2022","unstructured":"Sisakhtpour B, Mirzaei A, Karbasizadeh V et al (2022) The characteristic and potential therapeutic effect of isolated multidrug-resistant Acinetobacter baumannii lytic phage. Ann Clin Microbiol Antimicrob 21(1):1. https:\/\/doi.org\/10.1186\/s12941-022-00492-9","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"5302_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/23247096231188243","volume":"11","author":"A Hahn","year":"2023","unstructured":"Hahn A, Sami I, Chaney H et al (2023) Bacteriophage therapy for pan-drug-resistant Pseudomonas aeruginosa in two persons with cystic fibrosis. J Invest Med High Impact Case Rep 11:23247096231188243. https:\/\/doi.org\/10.1177\/23247096231188243","journal-title":"J Invest Med High Impact Case Rep"},{"key":"5302_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2022.101208","volume":"53","author":"T Nagel","year":"2022","unstructured":"Nagel T, Musila L, Muthoni M et al (2022) Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world. Curr Opin Virol 53:101208. https:\/\/doi.org\/10.1016\/j.coviro.2022.101208","journal-title":"Curr Opin Virol"},{"key":"5302_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s43088-021-00137-4","author":"NV Enwuru","year":"2021","unstructured":"Enwuru NV, Gill JJ, Anttonen KP et al (2021) Isolation and characterization of novel phage (Podoviridae \u0278ParuNE1) and its efficacy against multi-drug-resistant Pseudomonas aeruginosa planktonic cells and biofilm. Beni-Suef Univ J Basic Appl Sci. https:\/\/doi.org\/10.1186\/s43088-021-00137-4","journal-title":"Beni-Suef Univ J Basic Appl Sci"},{"key":"5302_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1344962","volume":"15","author":"P Manohar","year":"2024","unstructured":"Manohar P, Loh B, Turner D et al (2024) In vitro and in vivo evaluation of the biofilm-degrading Pseudomonas phage Motto, as a candidate for phage therapy. Front Microbiol 15:1344962. https:\/\/doi.org\/10.3389\/fmicb.2024.1344962","journal-title":"Front Microbiol"},{"issue":"8","key":"5302_CR30","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2460\/ajvr.72.8.1079","volume":"72","author":"TM Santos","year":"2011","unstructured":"Santos TM, Ledbetter EC, Caixeta LS et al (2011) Isolation and characterization of two bacteriophages with strong in vitro antimicrobial activity against Pseudomonas aeruginosa isolated from dogs with ocular infections. Am J Vet Res 72(8):1079\u20131086. https:\/\/doi.org\/10.2460\/ajvr.72.8.1079","journal-title":"Am J Vet Res"},{"issue":"1","key":"5302_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98457-z","volume":"11","author":"S Sharma","year":"2021","unstructured":"Sharma S, Datta S, Chatterjee S et al (2021) Isolation and characterization of a lytic bacteriophage against Pseudomonas aeruginosa. Sci Rep 11(1):19393. https:\/\/doi.org\/10.1038\/s41598-021-98457-z","journal-title":"Sci Rep"},{"key":"5302_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1386830","author":"Z Shi","year":"2024","unstructured":"Shi Z, Hong X, Li Z et al (2024) Characterization of the novel broad-spectrum lytic phage Phage_Pae01 and its antibiofilm efficacy against Pseudomonas aeruginosa. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2024.1386830","journal-title":"Front Microbiol"},{"key":"5302_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/v13071268","author":"D Liu","year":"2021","unstructured":"Liu D, Van Belleghem JD, de Vries CR et al (2021) The safety and toxicity of phage therapy: a review of animal and clinical studies. Viruses. https:\/\/doi.org\/10.3390\/v13071268","journal-title":"Viruses"},{"issue":"12","key":"5302_CR34","doi-asserted-by":"publisher","first-page":"7499","DOI":"10.1128\/aem.69.12.7499-7506.2003","volume":"69","author":"ST Abedon","year":"2003","unstructured":"Abedon ST, Hyman P, Thomas C (2003) Experimental examination of bacteriophage latent-period evolution as a response to bacterial availability. Appl Environ Microbiol 69(12):7499\u20137506. https:\/\/doi.org\/10.1128\/aem.69.12.7499-7506.2003","journal-title":"Appl Environ Microbiol"},{"key":"5302_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12040772","author":"AH Mondal","year":"2024","unstructured":"Mondal AH, Khare K, Saxena P (2024) A review on colistin resistance: an antibiotic of last resort. Microorganisms. https:\/\/doi.org\/10.3390\/microorganisms12040772","journal-title":"Microorganisms"},{"key":"5302_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11070839","author":"K Diallo","year":"2022","unstructured":"Diallo K, Dublanchet A (2022) Benefits of combined phage-antibiotic therapy for the control of antibiotic-resistant bacteria: a literature review. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics11070839","journal-title":"Antibiotics"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05302-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05302-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05302-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T13:19:50Z","timestamp":1770211190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05302-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5302"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05302-6","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was authorized by the ethical committee of the Ardabil University of Medical Science (IR.ARUMS.MEDICINE.REC.1402.061).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}